We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Medpace (MEDP) Outpaced the Stock Market Today
Read MoreHide Full Article
In the latest close session, Medpace (MEDP - Free Report) was up +1.18% at $496.41. The stock outperformed the S&P 500, which registered a daily gain of 0.47%. On the other hand, the Dow registered a gain of 0.11%, and the technology-centric Nasdaq increased by 0.94%.
Shares of the provider of outsourced clinical development services have appreciated by 7.16% over the course of the past month, outperforming the Medical sector's gain of 5.49%, and the S&P 500's gain of 2.32%.
The upcoming earnings release of Medpace will be of great interest to investors. The company's earnings per share (EPS) are projected to be $3.49, reflecting a 15.95% increase from the same quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $640.76 million, up 20.14% from the year-ago period.
MEDP's full-year Zacks Consensus Estimates are calling for earnings of $13.99 per share and revenue of $2.46 billion. These results would represent year-over-year changes of +10.77% and +16.83%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Medpace. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Medpace is currently a Zacks Rank #1 (Strong Buy).
Looking at valuation, Medpace is presently trading at a Forward P/E ratio of 35.07. This signifies a premium in comparison to the average Forward P/E of 16.7 for its industry.
One should further note that MEDP currently holds a PEG ratio of 3.09. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The average PEG ratio for the Medical Services industry stood at 1.5 at the close of the market yesterday.
The Medical Services industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 148, placing it within the bottom 41% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Medpace (MEDP) Outpaced the Stock Market Today
In the latest close session, Medpace (MEDP - Free Report) was up +1.18% at $496.41. The stock outperformed the S&P 500, which registered a daily gain of 0.47%. On the other hand, the Dow registered a gain of 0.11%, and the technology-centric Nasdaq increased by 0.94%.
Shares of the provider of outsourced clinical development services have appreciated by 7.16% over the course of the past month, outperforming the Medical sector's gain of 5.49%, and the S&P 500's gain of 2.32%.
The upcoming earnings release of Medpace will be of great interest to investors. The company's earnings per share (EPS) are projected to be $3.49, reflecting a 15.95% increase from the same quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $640.76 million, up 20.14% from the year-ago period.
MEDP's full-year Zacks Consensus Estimates are calling for earnings of $13.99 per share and revenue of $2.46 billion. These results would represent year-over-year changes of +10.77% and +16.83%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Medpace. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Medpace is currently a Zacks Rank #1 (Strong Buy).
Looking at valuation, Medpace is presently trading at a Forward P/E ratio of 35.07. This signifies a premium in comparison to the average Forward P/E of 16.7 for its industry.
One should further note that MEDP currently holds a PEG ratio of 3.09. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The average PEG ratio for the Medical Services industry stood at 1.5 at the close of the market yesterday.
The Medical Services industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 148, placing it within the bottom 41% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.